Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease - PubMed (original) (raw)

Review

Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease

Robert A Rissman et al. J Neurochem. 2011 May.

Abstract

In addition to progressive dementia, Alzheimer's disease (AD) is characterized by increased incidence of seizure activity. Although originally discounted as a secondary process occurring as a result of neurodegeneration, more recent data suggest that alterations in excitatory-inhibitory (E/I) balance occur in AD and may be a primary mechanism contributing AD cognitive decline. In this study, we discuss relevant research and reports on the GABA(A) receptor in developmental disorders, such as Down syndrome, in healthy aging, and highlight documented aberrations in the GABAergic system in AD. Stressing the importance of understanding the subunit composition of individual GABA(A) receptors, investigations demonstrate alterations of particular GABA(A) receptor subunits in AD, but overall sparing of the GABAergic system. In this study, we review experimental data on the GABAergic system in the pathobiology of AD and discuss relevant therapeutic implications. When developing AD therapeutics that modulate GABA it is important to consider how E/I balance impacts AD pathogenesis and the relationship between seizure activity and cognitive decline.

PubMed Disclaimer

References

1. Abou-Khalil BW. How important is Alzheimer's disease as a risk factor for unprovoked seizures and epilepsy in the elderly? Epilepsy Curr. 2010;10:36–37. -PMC -PubMed
1. Armstrong DM, Sheffield R, Mishizen-Eberz AJ, Carter TL, Rissman RA, Mizukami K, Ikonomovic MD. Plasticity of glutamate and GABAA receptors in the hippocampus of patients with Alzheimer's disease. Cell. Mol. Neurobiol. 2003;23:491–505. -PMC -PubMed
1. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell. Mol. Life Sci. 2004;61:657–668. -PMC -PubMed
1. Backus KH, Arigoni M, Drescher U, Scheurer L, Malherbe P, Mohler H, Benson JA. Stoichiometry of a recombinant GABAA receptor deduced from mutation-induced rectification. Neuroreport. 1993;5:285–288. -PubMed
1. Ballard TM, Knoflach F, Prinssen E, et al. RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) 2009;202:207–223. -PubMed

Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease - PubMed (original) (raw)